Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2002, p. 3641-3643, Vol. 46, No. 11
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.11.3641-3643.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Ministério da Saúde,1 Faculdade de Farmácia, Universidade Federal da Bahia,2 Hospital Couto Maia, Secretaria da Saúde do Estado da Bahia, Salvador, Brazil,3 Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, New York 100214
Received 4 June 2002/ Returned for modification 16 July 2002/ Accepted 5 August 2002
|
|
|---|
|
|
|---|
Active population-based surveillance for bacterial meningitis was established in Salvador, a city of more than 2 million inhabitants in northeastern Brazil. According to the state health secretary's regulations, suspected cases of meningitis from the metropolitan region of Salvador are referred to the state infectious disease reference hospital. More than 95% of the case notifications for meningitis from the metropolitan region are identified at this site (case notification records, Secretary of Health for the State of Bahia). Between March 1996 and October 2000, the study team prospectively identified 524 consecutives cases of meningitis with H. influenzae isolated from the cerebrospinal fluid. H. influenzae was identified based on Gram stain morphology and growth requirement for hemin and ß-NAD. Patients were enrolled into the study according to protocols approved by the institutional review board committees of the New York-Presbyterian Hospital and Oswaldo Cruz Foundation/Brazilian Ministry of Health. A sample of 150 (29%) isolates was randomly selected from the 524 identified during surveillance in order to achieve 4% precision for an observed prevalence value of 10% in the sample. The slide agglutination method was performed with type-specific antisera (Difco Laboratories, Detroit, Mich.) and identified 145 (95% of 150), 2 (1.3%), 2 (1.3%), and 1 (0.6%) isolates as serotypes b, a, nonencapsulated, and f, respectively.
The broth microdilution method was used to determine MICs (10). We evaluated susceptibility to antimicrobial agents used in the treatment of bacterial meningitis and acute respiratory infections for which H. influenzae is an etiologic agent: ampicillin, amoxicillin-clavulanic acid, cefotaxime, cefaclor, cefuroxime, chloramphenicol, ofloxacin, rifampin, tetracycline, co-trimoxazole (Sigma Chemical Co., St. Louis, Mo.), and azithromycin (Pfizer Ltd., Sao Paulo, Brazil). Antibiotics were added to the Haemophilus test medium (Difco Laboratories) in doubling dilution to give final concentrations ranging from 0.008 to 64 µg/ml. Microdilution trays were inoculated with a saline (0.9%) suspension of isolate strains to produce a final inoculum density of approximately 5 x 105 CFU/ml (100-µl final volume) and were examined for growth after 20 to 24 h of incubation at 35°C in ambient air. The MIC was defined as the lowest concentration of the antibiotic that inhibited growth. H. influenzae ATCC 49247 and 49766 were included as quality control standards in each assay (10). MIC determination showed that 10 (6.7% of 150) of the isolates were resistant to ampicillin, 16 (10.7%) to tetracycline, 12 (8.0%) to chloramphenicol, and 8 (5.3%) to co-trimoxazole (Table 1). All of the isolates tested were susceptible to cefuroxime, cefotaxime, ofloxacin, and azithromycin.
|
View this table: [in a new window] |
TABLE 1. Distribution of MICs for 150 H. influenzae isolates from meningitis cases in Salvador, Brazila
|
Nine of 10 (90%) ampicillin-resistant isolates were identified as ß-lactamase producers, while one was ß-lactamase negative and ampicillin resistant (BLNAR), according to the nitrocefin disk method (Cefinase; BBL Microbiology Systems, Cockeysville, Md.). All 139 ampicillin-susceptible isolates were ß-lactamase nonproducers, including the five isolates for which cefotaxime MICs were relatively elevated (0.25 to 1.0 µg/ml). Two isolates were resistant to amoxicillin-clavulanic acid; one was BLNAR while the other was ß-lactamase positive and amoxicillin-clavulanic acid resistant (BLPACR). The amoxicillin-clavulanic acid MICs for the BLNAR and BLPACR isolates were 8.0/4.0 µg/ml, whereas the cefotaxime MIC for only the BLNAR isolate was relatively elevated (1.0 µg/ml).
Our study found that a significant proportion (6.7%) of patients in Salvador, Brazil, developed meningitis due to strains resistant to ampicillin and chloramphenicol, antibiotics used routinely for the empirical treatment of bacterial meningitis in Brazil. These population-based findings corroborate those obtained from reference laboratory surveys in Brazil (2, 14) and South America (3), albeit in certain countries, such as Argentina, Chile, and Mexico (7), ampicillin resistance was identified in more than 20% of the clinical isolates. Together, these findings indicate that the choice of antibiotic regimen for the empirical treatment of bacterial meningitis may need to be reevaluated in Brazil and parts of South America where ampicillin and chloramphenicol are used. During surveillance in Salvador, all isolates were susceptible in vitro to third-generation cephalosporins, indicating that they would be an appropriate alternative. However, the cost of treating a patient with these alternative regimens can be up to 10 times greater than that for ampicillin and chloramphenicol (12) and represents a significant burden in regions such as Salvador, where the per capita public sector health expenditure is less than U.S. $20 each year.
Identification of H. influenzae BLNAR and BLPACR strains during surveillance in Salvador appears to be the first reported from Brazil and South America. The mechanism for resistance in BLNAR strains is believed to be associated with modifications in the penicillin binding proteins (13) and/or decrease in cell wall permeability (8). BLNAR strains may be resistant to ß-lactams in combination with a ß-lactamase inhibitor, as observed for the amoxicillin-clavulanic acid-resistant BLNAR isolate identified in this study and to first- and second-generation cephalosporins (1). Recent large surveys have not identified BLNAR and BLPACR among H. influenzae clinical isolates in South America (3, 6, 7). The isolation of these resistant strains in Salvador indicates that a new mechanism for drug resistance in H. influenzae may have recently emerged in this region.
Immunization with Hib conjugate vaccines is cost effective and is the priority for reducing the burden of H. influenzae disease and addressing antimicrobial-resistant Hib in South America. All ampicillin-resistant strains identified during surveillance for meningitis in Salvador were Hib. Hib conjugate vaccine campaigns in South America, such as that which was recently initiated in Brazil, will therefore provide the benefit of reducing future costs associated with treating antimicrobial-resistant Hib disease.
We thank the clinical and technical staff of Hospital Couto Maia for their assistance and cooperation; Edilane Gouveia, Ricardo M. Pinheiro, and Tatiana Silva Lôbo (Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS) for the collection of epidemiological data; Lee Riley and Warren Johnson, Jr. for their assistance in the design and implementation of the study; and most of all, the patients and their families.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»